End-of-day quote
Shanghai S.E.
06:00:00 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
60.04
CNY
|
-0.10%
|
|
+7.16%
|
+33.57%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,811
|
4,890
|
9,583
|
12,800
|
-
|
-
|
Enterprise Value (EV)
1 |
8,811
|
4,890
|
9,583
|
12,800
|
12,800
|
12,800
|
P/E ratio
|
68.9
x
|
37.6
x
|
59.1
x
|
55.2
x
|
38.7
x
|
28
x
|
Yield
|
-
|
-
|
0.89%
|
0.51%
|
0.79%
|
1.08%
|
Capitalization / Revenue
|
13.7
x
|
7.51
x
|
9.25
x
|
8.71
x
|
6.34
x
|
4.68
x
|
EV / Revenue
|
13.7
x
|
7.51
x
|
9.25
x
|
8.71
x
|
6.34
x
|
4.68
x
|
EV / EBITDA
|
41.1
x
|
21.4
x
|
29.4
x
|
29.4
x
|
21.8
x
|
16.4
x
|
EV / FCF
|
-
|
-
|
-
|
-26.8
x
|
-35.4
x
|
38.9
x
|
FCF Yield
|
-
|
-
|
-
|
-3.73%
|
-2.83%
|
2.57%
|
Price to Book
|
4.86
x
|
2.56
x
|
4.37
x
|
5.53
x
|
4.96
x
|
4.34
x
|
Nbr of stocks (in thousands)
|
213,184
|
213,184
|
213,184
|
213,184
|
-
|
-
|
Reference price
2 |
41.33
|
22.94
|
44.95
|
60.04
|
60.04
|
60.04
|
Announcement Date
|
2/27/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
643.9
|
651.3
|
1,036
|
1,470
|
2,018
|
2,735
|
EBITDA
1 |
-
|
214.2
|
228.3
|
326
|
434.7
|
587
|
780
|
EBIT
1 |
-
|
128.3
|
124.9
|
189.1
|
268.8
|
384.8
|
538
|
Operating Margin
|
-
|
19.93%
|
19.17%
|
18.26%
|
18.28%
|
19.06%
|
19.67%
|
Earnings before Tax (EBT)
1 |
-
|
125.7
|
123.2
|
170
|
257
|
362.7
|
510.3
|
Net income
1 |
123.4
|
115.4
|
129.1
|
161.3
|
231.5
|
329.2
|
456.2
|
Net margin
|
-
|
17.92%
|
19.82%
|
15.58%
|
15.75%
|
16.31%
|
16.68%
|
EPS
2 |
0.7700
|
0.6000
|
0.6100
|
0.7600
|
1.088
|
1.550
|
2.142
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-478
|
-362
|
329
|
FCF margin
|
-
|
-
|
-
|
-
|
-32.52%
|
-17.93%
|
12.03%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
42.18%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
72.11%
|
Dividend per Share
2 |
-
|
-
|
-
|
0.4000
|
0.3050
|
0.4750
|
0.6500
|
Announcement Date
|
4/25/21
|
2/27/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 Q3
|
---|
Net sales
|
-
|
-
|
EBITDA
|
-
|
-
|
EBIT
|
-
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
1 |
20.84
|
49.86
|
Net margin
|
-
|
-
|
EPS
|
0.1000
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
8/28/23
|
10/20/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-478
|
-362
|
329
|
ROE (net income / shareholders' equity)
|
-
|
7.97%
|
6.94%
|
8.18%
|
10%
|
12.8%
|
15.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
5.29%
|
6.12%
|
7.66%
|
9.37%
|
Assets
1 |
-
|
-
|
-
|
3,050
|
3,786
|
4,298
|
4,869
|
Book Value Per Share
2 |
-
|
8.500
|
8.960
|
10.30
|
10.90
|
12.10
|
13.80
|
Cash Flow per Share
2 |
-
|
0.8500
|
0.1400
|
1.640
|
1.540
|
1.000
|
1.130
|
Capex
1 |
-
|
233
|
438
|
659
|
391
|
377
|
227
|
Capex / Sales
|
-
|
36.19%
|
67.3%
|
63.64%
|
26.58%
|
18.68%
|
8.29%
|
Announcement Date
|
4/25/21
|
2/27/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
60.04
CNY Average target price
62.24
CNY Spread / Average Target +3.67% Consensus |
1st Jan change
|
Capi.
|
---|
| +33.57% | 1.78B | | +32.95% | 700B | | +26.51% | 569B | | -4.97% | 358B | | +18.83% | 330B | | +3.54% | 287B | | +15.70% | 236B | | +6.68% | 202B | | -9.08% | 197B | | +6.70% | 161B |
Other Pharmaceuticals
|